Recent News

• 05.14.2026 - Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ
• 05.07.2026 - Cardiol Therapeutics’ Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association
• 04.28.2026 - Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program
• 04.27.2026 - Heart Failure Is Getting Worse. Understanding Why Is the First Step.
• 04.21.2026 - Understanding Clinical Trials: What Each Stage Means and Why Phase III Matters
• 04.14.2026 - Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart
• 04.01.2026 - Cardiol Therapeutics Announces Year-End 2025 Update on Operations

Recent Filings

• 05.11.2026 - EX-99.1 EX-99.1
• 05.11.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.07.2026 - EX-99.1 EX-99.1
• 05.07.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.28.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.28.2026 - EX-99.1 EX-99.1
• 04.14.2026 - EX-99.1 EX-99.1
• 04.14.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.10.2026 - EX-99.1 EX-99.1
• 04.10.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]